By Matthew Pillar, Editor, Bioprocess Online
If you interview biopharma leaders by the hundreds as we do here at Life Science Connect, you’re going to get into some DE&I conversations whether you want to or not. When a “mission-driven” company (aren’t they all) codifies a commitment to DE&I, it’s considered PR gold. CxOs are coached on the talking points and become quite adept at weaving their intentions and philosophies into conversation. Most of the time, those talking points are light and fluffy and the value of their intentions is unquantifiable. “Diverse workforces bring diverse perspectives to drug development, and that’s valuable,” is the common refrain, buffeted by a catchy chorus of buzzwords that lack specific instruction or examples of DE&I at work.